13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
27 檔
33.9%
At the close of Q4 2025, Octagon Capital Advisors LP disclosed equity holdings valued at approximately $1.1B, spread across 27 reported holdings.
In Q4 2025, Octagon Capital Advisors LP adopted a defensive or profit-taking posture, trimming 10 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 12.38% | +3.55% | -42.94% | |
| 2 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 12.09% | -1.94% | — | |
| 3 | COGT | Cogent Biosciences Inc | Stock-Other | 10.13% | -1.84% | -18.24% | |
| 4 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 5.92% | +1.55% | -2.29% | |
| 5 | GOSS | Gossamer Bio Inc | Stock-Other | 5.24% | -0.17% | -18.38% | |
| 6 | KYMR | Kymera Therapeutics Inc | Stock-Other | 5.05% | -0.72% | +48.61% | |
| 7 | AVBP | Arrivent Biopharma Inc | Stock-Other | 4.81% | +1.12% | — | |
| 8 | TRVI | Trevi Therapeutics Inc | Stock-Other | 4.28% | -1.43% | — | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.87% | -1.14% | -0.02% | |
| 10 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.63% | — | +4.69% | |
| 11 | CGON | Cg Oncology Inc | Stock-Other | 3.02% | — | — | |
| 12 | ALMS | Alumis Inc | Stock-Other | 3.00% | +0.26% | — | |
| 13 | PALI | Palisade Bio Inc | Stock-Other | 2.73% | -0.06% | — | |
| 14 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.68% | — | -66.67% | |
| 15 | BIOA | Bioage Labs Inc | Stock-Other | 2.57% | +0.47% | — | |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.50% | -3.23% | EXIT | |
| 17 | RAPT | Rapt Therapeutics Inc | Stock-Other | 2.36% | — | — | |
| 18 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.28% | -3.30% | EXIT | |
| 19 | PHVS | Pharvaris N.V. | Stock-Other | 2.26% | +0.90% | -7.08% | |
| 20 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 2.08% | -0.70% | EXIT | |
| 21 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.59% | -0.71% | EXIT | |
| 22 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.34% | -0.48% | -43.60% | |
| 23 | EVMN | Evommune Inc | Stock-Other | 1.04% | -0.36% | EXIT | |
| 24 | DTIL | Precision Biosciences Inc | Stock-Other | 0.97% | -0.41% | — | |
| 25 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.94% | — | -14.35% | |
| 26 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.70% | -0.31% | — | |
| 27 | PEPG | Pepgen Inc | Stock-Other | 0.55% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | COGT | Cogent Biosciences Inc | +3.9% | -18.24% | Trim |
| 2 | KYMR | Kymera Therapeutics Inc | +2% | +48.61% | Add |
| 3 | TSHA | Taysha Gene Therapies Inc | +1.4% | -2.29% | Trim |
| 4 | TRVI | Trevi Therapeutics Inc | +0.4% | — | Unchanged |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 6 | PEPG | Pepgen Inc | +0.1% | — | Unchanged |
| 7 | UNCY | Unicycive Therapeutics Inc | 0% | — | Unchanged |
| 8 | BRD1EUR | Mind Medicine Mindmed Inc | -0.2% | +4.69% | Add |
| 9 | DBVT | Dbv Technologies Sa-spon Adr | -0.2% | -43.60% | Trim |
| 10 | BBOT | Bridgebio Oncology Therapeut | -0.2% | — | Unchanged |
| 11 | PHVS | Pharvaris N.V. | -0.5% | -7.08% | Trim |
| 12 | AVBP | Arrivent Biopharma Inc | -0.7% | — | Unchanged |
| 13 | 260 | Centessa Pharmaceuticals-adr | -0.8% | -9.64% | Trim |
| 14 | OCUL | Ocular Therapeutix Inc | -0.8% | -0.02% | Trim |
| 15 | CRBP | Corbus Pharmaceuticals Holdi | -1.2% | -14.35% | Trim |
| 16 | GOSS | Gossamer Bio Inc | -1.6% | -18.38% | Trim |
| 17 | CDTX | Cidara Therapeutics Inc | -1.7% | -66.67% | Trim |
| 18 | DNTH | Dianthus Therapeutics Inc | -2.3% | — | Unchanged |
| 19 | ABVX | Abivax Sa-adr | -4.7% | -42.94% | Trim |
| 20 | ✓ | Merus N V | — | EXIT | Sold out |
| 21 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 22 | ALMS | Alumis Inc | — | NEW | New buy |
| 23 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 24 | BIOA | Bioage Labs Inc | — | NEW | New buy |
| 25 | APLSUSD | Apellis Pharmaceuticals Inc | — | EXIT | Sold out |
| 26 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 27 | LXEO | Lexeo Therapeutics Inc | — | NEW | New buy |
| 28 | NUVB | Nuvation Bio Inc | — | EXIT | Sold out |
| 29 | EVMN | Evommune Inc | — | NEW | New buy |
| 30 | DTIL | Precision Biosciences Inc | — | NEW | New buy |
| 31 | MAZE | Maze Therapeutics Inc | — | EXIT | Sold out |
| 32 | NGNE | Neurogene Inc | — | EXIT | Sold out |
| 33 | GPCR | Structure Therapeutics Inc | — | EXIT | Sold out |
| 34 | NUVB-WS | Nuvation Bio Inc -cw27 | — | EXIT | Sold out |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 27 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, DNTH, COGT) accounted for 33.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
CGON
市值: $24.9M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $29.0M
During Q4 2025, Octagon Capital Advisors LP's top holdings by market value included ABVX (12.4%)、DNTH (12.1%)、COGT (10.1%). The largest single position, ABVX, represented 12.4% of total portfolio value.
In Q4 2025, Octagon Capital Advisors LP made 27 total portfolio adjustments, initiating 8 new buys, adding to 2 positions, trimming 10 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.